Evaluation and management of insomnia in clinical practice and in the time of CoViD-19 in Italy : expert consensus and task-force recommendations from five scientific societies
Insomnia symptoms might affect about 60% of the Italian population. Insomnia is a "24 hours syndrome" and a risk factor for medical and mental disorders. It should always be assessed and treated in the clinical practice. Cognitive Behavioral Therapy for Insomnia is the first line treatment but its availability in Italy is scarce. Pharmacological options in Italy are: melatonin 2 mg prolonged release that should be the first choice in subjects ≥55 years old and used until 13 weeks; and for a short term use (≤4 weeks) Z-drugs or short-acting benzodiazepines (in subjects <65 years old) or a sedating antidepressant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Rivista di psichiatria - 55(2020), 6 vom: 16. Nov., Seite 337-341 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Valutazione e trattamento dell’insonnia nella pratica clinica e ai tempi di CoViD-19 in Italia: raccomandazioni del panel di esperti e della task-force integrata di cinque società scientifiche |
|---|
| Beteiligte Personen: |
Palagini, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antidepressive Agents |
|---|
| Anmerkungen: |
Date Completed 30.12.2020 Date Revised 30.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1708/3503.34891 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319143511 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319143511 | ||
| 003 | DE-627 | ||
| 005 | 20231225170827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1708/3503.34891 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319143511 | ||
| 035 | |a (NLM)33349726 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Palagini, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation and management of insomnia in clinical practice and in the time of CoViD-19 in Italy |b expert consensus and task-force recommendations from five scientific societies |
| 246 | 3 | 3 | |a Valutazione e trattamento dell’insonnia nella pratica clinica e ai tempi di CoViD-19 in Italia: raccomandazioni del panel di esperti e della task-force integrata di cinque società scientifiche |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.12.2020 | ||
| 500 | |a Date Revised 30.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Insomnia symptoms might affect about 60% of the Italian population. Insomnia is a "24 hours syndrome" and a risk factor for medical and mental disorders. It should always be assessed and treated in the clinical practice. Cognitive Behavioral Therapy for Insomnia is the first line treatment but its availability in Italy is scarce. Pharmacological options in Italy are: melatonin 2 mg prolonged release that should be the first choice in subjects ≥55 years old and used until 13 weeks; and for a short term use (≤4 weeks) Z-drugs or short-acting benzodiazepines (in subjects <65 years old) or a sedating antidepressant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a GABA Agonists |2 NLM | |
| 650 | 7 | |a Hypnotics and Sedatives |2 NLM | |
| 650 | 7 | |a Receptors, Melatonin |2 NLM | |
| 650 | 7 | |a Sleep Aids, Pharmaceutical |2 NLM | |
| 700 | 1 | |a Manni, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Aguglia, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Amore, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Brugnoli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Girardi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Grassi, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Mencacci, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Plazzi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Minervino, Antonino |e verfasserin |4 aut | |
| 700 | 1 | |a Nobili, Lino |e verfasserin |4 aut | |
| 700 | 1 | |a Biggio, Giovanni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rivista di psichiatria |d 2009 |g 55(2020), 6 vom: 16. Nov., Seite 337-341 |w (DE-627)NLM194287742 |x 2038-2502 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2020 |g number:6 |g day:16 |g month:11 |g pages:337-341 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1708/3503.34891 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2020 |e 6 |b 16 |c 11 |h 337-341 | ||